Full Press Release Details
Remi Rabeuf, Director Corporate Alliances & Strategic Partnerships, talks us through his role, driving and coordinating activities to bring our Nu.Q ® NETs assay into the clinical and diagnostics market. This includes product development, gathering clinical evidence, regulatory approval, and increasing awareness and availability.
Remi also highlights the importance of working with key opinion leaders and centres of excellence to generate data and ensure successful market adoption for our Nu.Q ® NETs test.
“What I find very exciting is that we are the first company having a NET biomarker launch in the field that can help practitioners to improve sepsis management. We can contribute to improve mortality and comorbidities for those patients and contribute to save lives.”
Remi Rabeuf
Volition Life Cycle Leader
Related Articles
• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states
Data Showing the Prognostic Value of its Nu.Q® Cancer Test
Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states
• Share
• Tweet
• Share on Facebook
• Share
Subscribe for Volition product updates .
Or, click here for Investor Updates and press releases .
" * " indicates required fields